3SOF

Took a position before the close.

Ram

Another pick of mine that's taking off.

Ram

BVX making an ascending triangle. May be ready to take off in next few sessions.

Today seems the day to break out of this triangle pattern.

looking good

With the hindsight of yesterday's action it now looks as it was an easy pick. Symmetrical triangle formation, positive MACD divergence, MACD crossover all the breakout signals were there and to fuel the breakout management released this great news with perfect timing. Now it is time to relax and wait for momentum players to do the rest .

nice chart action today, also cant find any news except of :

Bovie Medical Gets FDA OK To Market Laparoscopic Tools
Dow Jones Newswires - October 12, 2006 7:39 AM ET

Bovie Medical Corp. (BVX) received clearance from the Food and Drug Administration to market a new line of modular laparoscopic electrosurgical electrodes and handle.

The Melville, N.Y., maker of electrosurgical medical products said the patent-pending instruments are aimed at the laparoscopic and arthroscopic markets.

Bovie said the total worldwide market for the product line is more than $200 million.

The company also named Gary Pickett chief financial officer. Pickett became Bovie's comptroller in March.

Quote from: la-onda on October 24, 2006, 07:10:31 PM
nice chart action today

Nice chart indeed laonda, BVX long term chart is very impressive

Financial Data:
http://www.boviemedical.com/ENfinancial.html


RECENT DEVELOPMENTS & NEW PRODUCTS:

* Revenues for the first nine months of 2006 increased over 33% to $19.75 million generating record net income of $2,259,899 or $.13 per diluted share.

* Revenues for third quarter increased 39% to a record $7.0 million resulting in net income of $856,959 or $.05 per diluted share.

* Acquired the assets of Lican Development LTD, which included proprietary patent pending technologies, working prototypes in various stages of development and production equipment.  Lican is a product development and manufacturing company focused on endoscopic devices.

* Received FDA marketing approval for new endoscopic modular forceps used in laparoscopic procedures.

* Oct. 2006 signed distribution and marketing agreement with Boston Scientific Corp. (BSX) for electrosurgical device for use in Oncology surgeries.

* Received FDA approval to market "In-a-Flash" suture removal device in July 2006. The device is designed to remove sutures with a tension free cut and is to be utilized in various human and animal medical procedures.

* The Company received FDA 510(k) marketing approval for its new GI generator. The Company's new GI device has been designed as a specialty electrosurgical niche product for the gastroenterological market.  The product design and styling adds a new dimension to Bovie's continued expansive array of generators.  Additionally, the product is expected to be the basis for entry into other niche markets.

* J-Plasma – The technology utilizes a gas ionization process allowing the surgeon to control temperatures and intensities, resulting in precision, minimal invasiveness and an absence of conductive currents during a medical procedure.  Management has determined that initial markets for J-Plasma will concentrate in dermatology, cosmetology, plastic surgery, gastroenterology and veterinary applications.


updated charts:

updated charts, from TA next days will be interesting IMHO

cheers
O.

update:

1)
BVX: Q2 EPS 6c vs 4c EPS +50% Y/Y
Friday , August 10, 2007 08:29ET

QUARTER RESULTS
Bovie Medical Corporation (BVX) reported Q2 results ended June 2007. Q2 Revenues were $7.44M; +10.39% vs yr-ago. Q2 EPS was 6c; +50.00% vs yr-ago.

2)
Bovie Medical, once the dominant brand of the electrosurgical industry, is working to rebuild its brand to its former glory

Written and produced by Lynn Haber & Thomas Venturo

Bovie Medical, once the dominant brand of the electrosurgical industry, is working to rebuild its brand to its former glory

Since 1998, the direction of Bovie Medical Corp. has revolved around the sale of battery operated cauteries and electrosurgical products; most notably, high frequency electrosurgical generators.

In fact, surgeons all over the world refer to their electrosurgical equipment and accessories as their "Bovie."

For the past two years, however, Bovie Medical has been undergoing a bit of self-surgery to drive the company in a new direction.

Fueled by the vision of company COO Moshe Citronowicz and his team, Bovie Medical — a publicly traded, $27 million company based in St.

Petersburg, Fla. — is focusing less on its OEM (Original Equipment Manufacturer) business and is investing heavily in research and development in proprietary echnology, which will ultimately be marketed under the Bovie label.

The company's new family of products, which it hopes to introduce in 2008, targets the area of minimally invasive surgery, a fast moving market estimated at approximately $1 billion that is currently dominated by just a few players.

To realize its vision, Bovie Medical is optimizing its proprietary technology in electrosurgery, and through acquisitions and partnerships is gaining access to additional technology, skills and intellectual property.

With two locations — St. Petersburg and another facility in Windsor, Canada — the company employs 150 people, approximately 12 percent of which are in engineering and development. By year end 2007, Bovie Canada expects to increase its current employee base of 12 to approximately 50.

The company team consists of marketing, development, sales, operations and quality, which are managed by the company's board members and Bovie Medical's president and CEO Andrew Makrides. Rob Saron is president of Bovie's sister company Aaron Medical.

History of Strength

The Bovie product line has changed hands several times prior to 1998.

The Bovie name was owned by Maxxim Medical prior to being purchased in
1998 by An-Con Genetics Inc. NY (now Bovie Medical), which had acquired Aaron Medical Industries. Today, Bovie Medical is the parent of Aaron Medical.

After Aaron was purchased in 1995, money was invested in R&D to develop a line of electrosurgical products. Today, products are developed under the Aaron and Bovie names, but sold through separate distribution lines – general distribution lines carry Aaron products, which are sold to the physician market; whereas specialty distributors handle Bovie products, which are sold to hospitals.

Although Bovie is a household name used generically for all electrosurgery products among surgeons, a period of time elapsed before products were commercialized under the brand synonymous with electrosurgery. It was in the late 1920s, when Dr. William T. Bovie invented and first used the Bovie electrosurgical generator in an operating room.

Under the direction of Citronowicz and his team, the company aims to resurrect the Bovie name in electrosurgery as it makes its way into the market of minimally invasive surgery with new niche market products.

The change in course began approximately two years ago when the company decided to focus less on its OEM business — which accounts for approximately 30 percent of the company's business — and more on new niche markets.

"We have unique proprietary technology and our own distribution channels. Going forward we're optimizing our accessories and our generators to create a specialized effect not possible with standard generators and standard accessories," says Rick Pfahl, VP of proprietary instrument technology.

To do that, the company, rich in electrosurgical proprietary technology, needed additional capabilities that it didn't have in-house, especially in metal forming capabilities for its proprietary instrument technology.

In January 2006, the company acquired patent pending technology for new endoscopic modular instruments from Windsor, Canada-based Henvil Corp., a former vendor of Bovie Medical.

Henvil founder and President Steve Livneh reportedly had up to 15 patents that focused on medical instrumentation.

In November 2006, Bovie purchased the Windsor facility — now called Bovie Canada — and has since expanded the number of patents and products developed and manufactured there. The products are expected to be commercialized in mid-2008.
The target market for the new family of products that compliment related generator products is primarily hospitals and surgery centers, worldwide.

Today, Bovie Medical products compete in a market over one billion dollars. Bovie recognizes an opportunity to grow its market base substantially and increase sales significantly. Currently, approximately 17 percent of Bovie's revenue is international.

The company will leverage the Bovie brand name, proprietary technologies, and the expertise it has acquired in its OEM business – namely quality manufacturing processes. Bovie has developed the infrastructure to propel itself forward.

"We have a lot of intellectual property in generators and instrumentation and have partnered well with industry leaders," says Citronowicz.

In particular, he refers to intellectual property in the area of plasma accessory technology and the company's partnership with Canady Technology. Founder Dr. Jerome Canady, holds more than a dozen plasma related patents and is recognized as a clinical expert in plasma technology.

Distribution and manufacturing agreements between the two companies were announced in June 2007.

Bovie Medical's reach for product expertise is continuing and the company searches for expertise, worldwide.

"Dealing in global markets we understand that competition can come from anywhere. It's an ongoing effort to improve our technology and processes," says Citronowicz.
The company has strategic partnerships for technology, brain power and manufacturing in countries such as Bulgaria, Canada, China, Israel, Russia, and the U.K. For example, when they needed the best technology for printed circuit boards they reached out to Baya Technology in Tel Aviv, Israel, as they were able to provide unique solutions.

Bovie Medical executives say they realize that without the availability of sophisticated computer and communications technology, its worldwide efforts wouldn't be possible. The company and its far flung partners rely heavily on the Internet and Voice over Internet Protocol (VoIP) for voice calls and videoconferencing, and email to overcome language and time zone challenges.

Looking forward

Over the next year — as the company brings new electrosurgery products to the minimally invasive surgery electrosurgery market — Bovie Medical will rely on its existing distribution strategy that relies on partners rather than a direct sales force.

"Our distribution strategy doesn't restrict us from seeking out the best partners for our specialty products. In fact, it enables us to partner with the best distributors for the markets in which we participate," explains Pfahl.

In place since 1998, Bovie Medical's distribution strategy has been tested and proven for the company, which expects it to keep improving as the company moves forward.
Bovie Medical trains its distribution network and its distributors train end users. The network includes more than 100 distributor partners. In all, Bovie is well positioned as it is on the verge of launching an ambitious growth strategy that could allow the company to enter into a new and emerging worldwide marketplace.

3) chart:
very very tight bollinger bands...

looks promising....

Bovie Medical Corporation Announces Fourth Quarter and Fiscal 2007 Results: Reports Continued Progress on New Products
Monday , March 31, 2008 07:00ET

MELVILLE, N.Y., Mar 31, 2008 (BUSINESS WIRE) -- Bovie Medical Corporation (the "Company") (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced fourth quarter and fiscal year 2007 results.

For the quarter ended December 31, 2007, revenue rose 4 percent to a fourth quarter record $7.2 million versus $6.9 million recorded in the same period last year, resulting in net income of $280,778 or $.02 per diluted share, compared to net income of $423,307 or $.02 per diluted share in the prior year. (Income from operations before income tax totaled $458,135 for the fourth quarter of fiscal 2007 compared to $433,307 in 2006).

For the fiscal year ended December 31, 2007, revenues increased 8% to a record $28.78 million versus $26.68 million a year earlier. Net income totaled $2,400,591 or $.14 per diluted share compared to $2,683,206 or $.16 per diluted share last year.

The Company recognized a provision for income taxes of approximately $871,000 during fiscal year 2007, which provision was negligible in 2006. The Company will be required to continue recognizing an expense for income taxes in those periods in which it generates positive results from operations. However, we will not be responsible for the actual payment of any income taxes other than those arising from the alternative minimum tax, until the Company fully utilizes its operating loss carryforwards for tax purposes in the second half of 2008.

Andrew Makrides, president of Bovie, stated, "As we look ahead we remain confident that the development of our new proprietary products will provide significant future growth as we expand into new markets. The advances and efforts during fiscal 2007 were supported entirely by internal cash flow, demonstrating a strong financial infrastructure, with a balance sheet characterized by a solid cash position and zero long-term debt. Additionally, Bovie continues serious discussions with other companies that could positively impact us going forward."

New Product Update

Endoscopic Modular Instruments (MEG Line) - The patent-pending modular forceps and accessories are designed to provide surgeons added comfort and improved safety combined with reducing per-procedure costs through the reduction of inventory and obsolescence. The proprietary instruments offer a simpler assembly process for laparoscopic procedures and are the first modular forceps designed for the arthroscopic market. There has been added progress and improvements on the original FDA cleared design, and the Company anticipates submitting its latest version to the FDA and the European Union for a CE mark shortly. Plans for distribution in Europe are being implemented. Production and sales are expected to commence by the end of the second quarter.

Polarian Handle and Accessories - The patent-pending Polarian surgical handle supports a plurality of electrical and mechanical modes to be used in conjunction with disposable, Seal-N-Cut bipolar cartridges. The advanced Polarian technology will be a new entrant into the rapidly growing vessel and tissue sealing area with the commencement of marketing anticipated by year's end.

ICON GP/VS - This generator is being developed from our ICON technology platform. It is designed to improve safety and convenience in performing general purpose procedures and includes advanced vessel sealing components integrated with our Polarian handpiece and accessories.

ICON GS Plasma System - The ICON GS will be the first commercial product based on the Company's J-Plasma technology. The development of this new helium gas system generator (utilizing the ICON technology) includes the design of a new proprietary handpiece.

This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company's SEC filings.



BVX: New 52-Wk High @ $8.360 up 4.50%
Tuesday , April 22, 2008 13:30ET

This is the 1st 52 WEEK HIGH alert for BVX in the past 7 calendar days.

The share price for Bovie Medical Corporation (AMEX: BVX) reached a new 52-week high today, trading at $8.360, up $0.360 (4.50%) from its previous close of $8.000.

The Company's previous 52-week high of $8.210 was set 194 days ago on October 11, 2007.

One year ago, the Company's shares closed at $7.110. The price has climbed more than 17 percent since then.

At the time of this alert, the stock had traded 36,259 shares via 71 trades, 25.98% below it's 20day average of 48,984 shares.

This new 52-week high currently puts the stock:

16.73% above its 20day Moving Average of $7.162
29.10% above its 50day Moving Average of $6.476
32.24% above its 100day Moving Average of $6.322

BVX: Submits 510(k) Application to FDA for J-Plasma System

Bovie Medical Corporation (BVX) has submitted a 510(k) pre-market notification application to the FDA requesting regulatory clearance for its ICON GS electrosurgical generator and handpiece (J-Plasma system).

The technology utilizes a gas ionization process producing a stable thin focused beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon greater precision, minimal invasiveness and an absence of conductive currents during surgery. Recent engineering improvements include increases in power and efficiency and component miniaturization, making manufacturing easier and more efficient.

Management is considering possible uses in several surgical procedures including dermatology and plastic surgery as well as several other surgical specialties.

Not liking the chart or the volume at this time.
But who knows 
JMHO...